S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

Introduction: Thymic carcinoma is a rare and aggressive malignancy with few treatment options. Preclinical studies suggested that targeting the angiogenic pathway may be beneficial in this disease. Methods: This randomized phase 2 trial enrolled patients with unresectable, locally advanced, recurren...

Full description

Saved in:
Bibliographic Details
Main Authors: Anne S. Tsao, MD, MBA, Ming-Hui Hsieh, MS, Marianna Koczywas, MD, Janet Tu, MD, Jonathan Riess, MD, MS, Tawee Tanvetyanon, MD, Barbara T. Ma, MD, Ying-Qi Zhao, PhD, Mary W. Redman, PhD, Martin J. Edelman, MD, David R. Gandara, MD, Jhanelle E. Gray, MD, Karen L. Kelly, MD
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:JTO Clinical and Research Reports
Subjects:
Thymic carcinoma
Ramucirumab
Chemotherapy
Carboplatin-paclitaxel
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364324001085
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2666364324001085

Similar Items